Multicenter clinical trial, randomized phase II "window of opportunity" which aims to test the biological activity of abiraterone acetate administered as neoadjuvant therapy in patients with prostate cancer at high risk. (multicenter study).
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2014
At a glance
- Drugs Abiraterone acetate (Primary) ; LHRH receptor agonists
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 Jul 2014 New trial record